EDIT vs PRME
EDIT: A gene editing pioneer leveraging CRISPR technology to develop in vivo, one-time therapies for serious genetic diseases. PRME: Prime Medicine is pioneering a versatile and precise "search-and-replace" gene editing platform to create potentially curative, one-time therapies for severe genetic diseases.
Side-by-side fundamentals
| Metric | EDIT | PRME | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $2.84 | $3.58 | |
| Market cap as of 2026-07-31 (share count; price 2026-10-08) | $436M | $649M | |
| Net margin FY2025, SEC XBRL | -395.0% | -4342.4% | EDIT higher |
| Operating margin FY2025, SEC XBRL | -394.9% | -4498.1% | EDIT higher |
| ROE FY2025, SEC XBRL | -586.6% | -166.4% | PRME higher |
| ROA FY2025, SEC XBRL | -85.8% | -58.7% | PRME higher |
| Debt / equity as of 2026-09-03 | 0.53 | 0.00 | PRME lower |
| Revenue growth (YoY) as of 2026-09-03 | +20.8% | -17.9% | EDIT higher |
| Revenue CAGR (3y) SEC XBRL | +27.1% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 2.23 | 2.01 | |
| 1-year return as of 2026-10-08 close | -31.6% | -44.5% | EDIT higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.